FME.HM Fresenius Medical Care AG & Co. KGaA
- Market cap
- -
- P/E
- 11.8x
- P/B
- 0.86x
- ROE
- 5.4%
- Dividend yield
- 2.82%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is FME.HM undervalued?
Graham numberThe Graham number of Fresenius Medical Care AG & Co. KGaA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Fresenius Medical Care AG & Co. KGaA fundamental analysis
No fundamental analysis for Fresenius Medical Care AG & Co. KGaA yet.
Fresenius Medical Care AG & Co. KGaA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Fresenius Medical Care AG & Co. KGaA
There is no Profile data available for FME.HM.
Full company profileFresenius Medical Care AG & Co. KGaA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Fresenius Medical Care AG & Co. KGaA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 17.0B | 17.8B | 16.5B | 17.5B | 17.9B | 17.6B | 19.4B | 19.5B | 19.3B | 19.6B | 18.9B |
| Gross Profit | 5.50B | 6.00B | 5.15B | 5.40B | 5.54B | 4.77B | 4.89B | 4.93B | 4.76B | 5.03B | 4.98B |
| Operating Income | 2.45B | 2.30B | 2.16B | 2.17B | 2.21B | 1.86B | 1.45B | 1.48B | 1.47B | 1.83B | 1.83B |
| EBITDA | - | 3.14B | 3.91B | 3.92B | 2.35B | 1.93B | 3.42B | 3.21B | 3.21B | 3.40B | 3.21B |
| Net Income | 1.18B | 1.28B | 1.98B | 1.20B | 1.16B | 969M | 673M | 499M | 538M | 978M | 672M |
| EPS | - | 4.18 | 6.46 | 4.02 | 3.98 | 3.31 | 2.30 | 1.70 | 1.83 | 3.50 | 2.52 |
| Balance Sheet | |||||||||||
| Total Assets | 25.6B | 24.0B | 26.2B | 32.9B | 31.7B | 34.4B | 35.8B | 33.9B | 33.6B | 31.0B | 31.3B |
| Total Liabilities | 14.7B | 13.2B | 13.3B | 19.7B | 19.4B | 20.4B | 20.3B | 19.1B | 17.8B | 16.7B | 17.8B |
| Shareholders' Equity | 10.3B | 9.82B | 11.8B | 12.0B | 11.2B | 12.7B | 14.0B | 13.6B | 14.6B | 13.3B | 12.6B |
| Cash & Short-term Investments | 710M | 978M | 2.15B | 1.01B | 1.08B | 1.48B | 1.27B | 1.38B | 1.15B | 1.58B | 1.06B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.03B | 2.19B | 2.06B | 2.57B | 4.23B | 2.49B | 2.17B | 2.63B | 2.39B | 2.68B | 2.17B |
| Capital Expenditure | 979M | 944M | 1.06B | 1.12B | 1.05B | 854M | 724M | 685M | 699M | 915M | 861M |
| Free Cash Flow | - | 1.25B | 1.00B | 1.44B | 3.18B | 1.64B | 1.44B | 1.94B | 1.69B | 1.77B | 1.31B |
| Ratios | |||||||||||
| ROE | 11.5% | 13.0% | 16.9% | 10.0% | 10.4% | 7.6% | 4.8% | 3.7% | 3.7% | 7.4% | 5.4% |
| ROA | 4.6% | 5.3% | 7.6% | 3.6% | 3.7% | 2.8% | 1.9% | 1.5% | 1.6% | 3.2% | 2.1% |
| Net Profit Margin | 6.9% | 7.2% | 12.0% | 6.9% | 6.5% | 5.5% | 3.5% | 2.6% | 2.8% | 5.0% | 3.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Fresenius Medical Care AG & Co. KGaA dividends
- Dividend yield
- 2.82%
- Forward dividend
- -
- Payout ratio
- 43.2%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 423M | 1.51 | 43.2% |
| 2024 | EUR 349M | 1.19 | 64.9% |
| 2023 | EUR 329M | 1.12 | 65.9% |
| 2022 | EUR 396M | 1.35 | 58.7% |
| 2021 | EUR 392M | 1.34 | 40.5% |
| 2020 | EUR 351M | 1.20 | 30.2% |
| 2019 | EUR 355M | 1.19 | 29.6% |
| 2018 | EUR 325M | 1.06 | 16.4% |
| 2017 | EUR 294M | 0.96 | 23.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Fresenius Medical Care AG & Co. KGaA
Ownership data of Fresenius Medical Care AG & Co. KGaA is not available yet.
Fresenius Medical Care AG & Co. KGaA company profile
- Company name
- Fresenius Medical Care AG & Co. KGaA
- Ticker
- FME.HM
- Exchange
- Hamburg Exchange
- Sector
- Other
- Industry
- Metals & Mining
- Fiscal year end
- December
- Address
- Website
- -
About Fresenius Medical Care AG & Co. KGaA
There is no Profile data available for FME.HM.